Stocksigma LogoStocksigma Logo

Venmax Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26

■ Revenue: 528 (+300.6% YoY | +113.0% QoQ) ■ EBITDA: 20.1 (+329.7% YoY | +71.1% QoQ) ■ EBITDA Margin (%): 3.8 (+26 bps YoY | -93 bps QoQ) ■ PAT: 12.0

Venmax Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26

Venmax Drugs and Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 9:31 pm

Venmax Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 528 (+300.6% YoY | +113.0% QoQ) ■ EBITDA: 20.1 (+329.7% YoY | +71.1% QoQ) ■ EBITDA Margin (%): 3.8 (+26 bps YoY | -93 bps QoQ) ■ PAT: 12.0 (+393.0% YoY | +3.2% QoQ) ■ EPS (INR): 0.08 (+60.0% YoY | -20.0% QoQ)

Original exchange filing (PDF)

More announcements from Venmax Drugs and Pharmaceuticals Ltd

All Venmax Drugs and Pharmaceuticals Ltd announcements